By Stephen Nakrosis
The Food and Drug Administration approved Mirum Pharmaceuticals' Ctexli to treat Cerebrotendinous Xanthoma, a very rare lipid-storage disease.
The approval makes Ctexli, or chenopod, the first FDA-approved drug to treat CTX, the agency said Friday.
Patients with CTX are unable to break down cholesterol in a normal way, which can result in damage to the brain, liver, and skin and tendons, the FDA said.
The FDA also said the recommended dosage is 250 milligrams, taken orally three times a day.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
The Food and Drug Administration approved Mirum Pharmaceuticals' Ctexli, or chenodiol, to treat Cerebrotendinous Xanthoma, the agency said Friday. "FDA Approves Mirum Pharmaceuticals Treatment for Lipid-Storage Disease," at 1:04 p.m. ET, incorrectly said the treatment was chenopod.
(END) Dow Jones Newswires
February 21, 2025 17:49 ET (22:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。